Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnologica 1999 June;11(2) > Minerva Biotecnologica 1999 June;11(2):139-52

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

  FLOW CYTOMETRY IN IMMUNOLOGY AND HEMATOLOGY 

Minerva Biotecnologica 1999 June;11(2):139-52

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: English

The immunophenotyping of acute leukemias

Basso G.

Dipartimento di Scienze Pediatriche e dell’Adolescenza, Università degli Studi,Torino, Italy


PDF


The immu­no­phen­o­typ­ing of ­acute leu­ke­mi­as is ­today the pre­ferred meth­od for per­form­ing the iden­tifi­ca­tion, enu­mer­a­tion and char­ac­ter­iza­tion of ­blast ­cells at diag­no­sis. In ­spite of its wide­spread ­present util­iza­tion, ­there ­does not ­exist a stan­dard­ized pro­to­col in clin­i­cal labor­a­to­ries to ­achieve ­inter-labor­a­to­ry repro­du­cibil­ity ­using the ­most infor­ma­tive pro­ce­dures. The com­plex­ity of ­most com­mon ques­tions in ­acute leu­ke­mia immu­no­phen­o­typ­ing, diag­no­sis and eval­u­a­tion of min­i­mal resid­u­al dis­ease, ­demands the util­iza­tion of the major­ity of pos­sible infor­ma­tion. The mul­ti­par­a­met­ric immu­no­phen­o­typ­ing ­approach ­using ­three col­ors simul­ta­ne­ous­ly is report­ed ­here. This ­approach is ­based on an ade­quate ­choice of ­reagents, and on sam­ple prep­ar­a­tion ­using ­whole ­blood. Recent ­data ­show ­that ­three col­or anal­y­sis is an ade­quate meth­od to ­achieve a ­clear dis­crim­i­na­tion ­between nor­mal and path­o­log­i­cal ­cells, in ­order to per­form the diag­no­sis, clas­sifi­ca­tion and prog­no­sis of ­acute leu­ke­mi­as. One col­or is ­used for the immu­no­log­i­cal ­gate, in ­fact ­this is the ­best meth­od for the leu­kem­ic ­cell iden­tifi­ca­tion, and the fol­low­ing anal­y­sis is per­formed in ­blast-gat­ed bipar­a­met­ric his­to­grams. The pro­ce­dure ­must be dis­sim­i­lar in lym­pho­blas­tic and myel­o­blas­tic leu­ke­mi­as, ­because the diag­nos­tic ques­tions are dif­fer­ent for het­ero­ge­ne­ity and clo­nal­ity of malig­nant ­cells. The use­ful meth­od to ­define pos­i­tive anti­gen cri­te­ria is the quan­tifi­ca­tion of anti­gens, ­using pre-cal­i­brat­ed ­sets of flu­o­res­cent ­beads. This meth­od per­mits a ­cross eval­u­a­tion of immu­no­phen­o­typ­ing ­results ­between dif­fer­ent inves­ti­ga­tors and labor­a­to­ries. Recent ­reports indi­cate ­that the phe­no­typ­ic aber­ra­tions ­reflect genet­ic abnor­mal­ities of leu­kem­ic ­cells and there­fore ­their def­i­ni­tion and iden­tifi­ca­tion ­seem rel­e­vant for prog­nos­tic impli­ca­tions and for min­i­mal resid­u­al dis­ease iden­tifi­ca­tion.

top of page